Counterfeit Drugs
MaryAnn Hegedus
Colorcon
The current estimate is that by 2010, counterfeiting will cost pharmaceuticalmanufacturers
$75 billion.
 

Early Research

Dr. Martin Mackay
Pfizer Global Research and Development
By combining the information from different clinical trials we can avoid conducting clinical trials that are not likely to be successful.
 

Salesforces

Celeste Mosby
Wilson Learning Worldwide

Succeeding in an ever-changing and tightly regulated environment will be based on the value that reps bring to healthcare providers. 

We continue to invest heavily in
new technologies. Transactions such as
these open the way to developing
new and better diagnostic tests and
treatments for complex diseases.
November/December 2008

    The industry started feeling the pinch of belt-tightening almost a decade ago, slowly at first. But today’s pressures must feel like a vise grip. Being squeezed from all sides, life-sciences companies are having to counter multiple challenges of tremendous magnitude: increased regulatory scrutiny, the need to control costs, generic competition, pricing pressures, and reputation management, to name just a few. Historically slow to change course, but with a world of new obstacles to navigate, the industry will need to transform itself into a more nimble, forward-thinking, patient-centric entity.  




       

WebSeminars - Register Today!

PharmaVOICEMarketplace - Directory of Service Providers


Ken Ribotsky

Core-Create

Regulating bodies, both government and industry, must realize that the train has already left the station,” he says. “It is simply irresponsible not to allow manufacturers and brand teams to be part of a machine that provides the opportunity to disseminate quality information, as well as to correct misinformation, in real time.

 

 Become a Member

  Search    Go 
  Advanced Search

Privacy and Legal Statement |  Site Map |  About Us |  Contact Us |  VIEWs |  Podcasts |  WebLinx WebSeminars |  E-Surveys | PharmaLinx.com